CBST News Alert Cubist Pharmaceuticals (CBST) 100.29 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cubist Pharmaceuticals (CBST) 100.29 $CBST

Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen Plunges on Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 24, 8:48AM CST
Will Express Scripts' announcement regarding AbbVie's (ABBV) Viekira Pak lead to a pricing war in the hepatitis C virus (HCV) market?
BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), IMGN: 5.90 (+0.13), ABBV: 66.21 (+1.86)

Auxilium's Xiapex Gets CHMP Nod for Peyronie's Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:10PM CST
Auxilium Pharmaceuticals (AUXL) and partner Sobi's Xiapex is a step closer to EU approval with the CHMP giving a favorable opinion for the treatment of adult men suffering from Peyronie's disease.
ENDP: 72.10 (+0.34), CBST: 100.29 (-0.09), AUXL: 34.40 (+0.18), BIOD: 1.36 (-0.04)

Jim Cramer on the Markets: Some Stocks You Just Can't Ignore
at The Street - Tue Dec 23, 9:03AM CST
And stop chasing stocks that won't let you in.
FDX: 176.42 (-0.52), MMM: 166.96 (+0.09), SWKS: 74.32 (+0.92), NKE: 96.29 (+0.32), HON: 101.96 (-0.02), DIS: 94.42 (-0.27), BA: 131.24 (+1.21), MS: 38.81 (-0.14), AA: 15.77 (+0.04), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), COST: 143.65 (-0.50), CVS: 97.89 (+0.02), MCD: 93.83 (-0.39), GOOGL: 536.93 (-1.84), ROST: 92.72 (-0.60)

Watch for Cubist Pharmaceuticals to Potentially Pullback After Gaining 1.82% Yesterday
Comtex SmarTrend(R) - Mon Dec 22, 3:53PM CST
Cubist Pharmaceuticals (NASDAQ:CBST) traded in a range yesterday that spanned from a low of $100.15 to a high of $100.97. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $99.25 on volume of 6.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CBST: 100.29 (-0.09)

Cubist's Antibiotic Zerbaxa Wins FDA Nod for cUTI and cIAI - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:30PM CST
Cubist's (CBST) antibiotic, Zerbaxa gained FDA approval for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections.
ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), BIOD: 1.36 (-0.04)

Pharma Deals Watch: Coverage Initiated on AstraZeneca, Advaxis, Radius Health, Cubist and AbbVie
PR Newswire - Mon Dec 22, 8:00AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including AstraZeneca (NYSE: AZN), Advaxis (NASDAQ: ADXS), Radius Health (NASDAQ: RDUS), Cubist (NASDAQ: CBST), and AbbVie (NYSE: ABBV). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
RDUS: 37.17 (+0.11), ADXS: 7.57 (+0.50), CBST: 100.29 (-0.09), AZN: 70.44 (+0.26), ABBV: 66.21 (+1.86)

Merck begins tender offer to acquire Cubist
M2 - Mon Dec 22, 6:43AM CST
Healthcare company Merck (NYSE:MRK) said on Friday that its subsidiary has started a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals (NasdaqGS:CBST).
CBSTZ: 0.06 (+0.01), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)

FDA approves Cubist's Zerbaxa
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 5:35PM CST

CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)

Cubist Announces FDA Approval of New Antibiotic ZERBAXA(TM) (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections
Business Wire - Fri Dec 19, 5:08PM CST
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today the U.S. Food and Drug Administration (FDA) approved ZERBAXA(TM) (ceftolozane/tazobactam) for the treatment of adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) caused by designated susceptible Gram-negative bacteria.
CBST: 100.29 (-0.09)

Merck Up on OncoEthix Acquisition Deal, Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 4:20PM CST
Merck (MRK) acquired Swiss biotech privately held company, OncoEthix, and added a promising experimental early-stage candidate, OTX015, to its oncology portfolio.
AGN: 210.12 (+0.95), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), ABBV: 66.21 (+1.86)

Tetraphase Spikes on Encouraging Data on Antibiotic - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:19PM CST
Tetraphase Pharmaceuticals, Inc. announced positive top-line data from a phase III study evaluating eravacycline for the treatment of complicated intra-abdominal infection.
JNJ: 104.59 (+0.31), TTPH: 38.86 (+0.53), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)

Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)

Cubist Pharmaceuticals (CBST) Showing Signs Of Being A Momo Momentum Stock
at The Street - Fri Dec 19, 8:45AM CST
Trade-Ideas LLC identified Cubist Pharmaceuticals (CBST) as a momo momentum candidate
CBST: 100.29 (-0.09)

Merck Begins Tender Offer to Acquire Cubist
Business Wire - Fri Dec 19, 7:00AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ:CBST). On Dec. 8, 2014, Merck announced its intent to acquire Cubist.
CBSTZ: 0.06 (+0.01), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)

NPS Pharmaceuticals and Shire Up on Takeover Rumors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 5:30PM CST
A report from Bloomberg indicated that the Shire is considering a potential acquisition of the NPS Pharma.
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), SHPG: 209.29 (+0.07), NPSP: 35.06 (+1.18), ABBV: 66.21 (+1.86)

PDUFA date approaches for Cubist antibiotic combo
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 11:29AM CST

CBST: 100.29 (-0.09)

Tetraphase Jumps As 'Superbug' Drug Scores In Trial
at Investor's Business Daily - Thu Dec 18, 10:54AM CST
Biotech Tetraphase Pharmaceuticals (TTPH) jumped 16% to a new high Thursday and got a volley of price target increases after it reported positive trial results for its antibiotic late Wednesday. The trial found Tetraphase's eravacycline to be...
TTPH: 38.86 (+0.53), ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)

Shares of CBST Up 46.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 17, 4:47PM CST
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 2 months, Cubist Pharmaceuticals has returned 46.52% as of today's recent price of $97.81.
CBST: 100.29 (-0.09)

Cubist Pharmaceuticals: An Extraordinary Arbitrage Opportunity
Shareholder Boar - at Seeking Alpha - Wed Dec 17, 10:26AM CST

CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)

Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 17, 9:26AM CST
It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline updates.
CYCC: 0.69 (+0.01), CBST: 100.29 (-0.09), SPHS: 0.46 (+0.02), CCXI: 6.64 (-0.04), ALXN: 181.96 (+3.09), EXEL: 1.29 (-0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 121

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Protein Now! Gains Clinician Attention, With Caveats

Updated Category News Views 91

A Small Bottle Has Drawn a Crowd Protein powder tubs have been cluttering kitchens for years; a 3.38-fluid-ounce shot is a cleaner answer to the same daily hassle. NutraBio Labs says more than 800 physicians, nurse practitioners, and physician associates had added PROTEIN NOW! to their individual FrontrowMD patient pages as of November 2026. That earned the product a...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading

Top 5 Most Recently Viewed Articles

Molina Healthcare: A Journey of 20 Years of Returns

Updated Category News Views 197

Molina Healthcare's Impressive Investment Journey Molina Healthcare (NASDAQ: MOH) has consistently outperformed the broader market over the last two decades, achieving an impressive annualized return of 12.15%. As a result, this sector leader has garnered significant attention from investors and analysts alike, showcasing its robust performance in the healthcare industry....

Continue Reading
Nokia's Strategic Buyback Program to Enhance Shareholder Value

Updated Category News Views 232

Nokia's Strategic Share Repurchase Initiative Nokia Corporation (NYSE:NOK) has embarked on a significant share repurchase program aimed at mitigating the dilution effects from recent share issuances. This initiative aligns with the company's ongoing commitment to enhancing shareholder value. Recently, Nokia executed the acquisition of 872,093 shares at an average price of...

Continue Reading
Justin Boots Unveils Stylish New Baby Boot Line for First Steps

Updated Category News Views 185

Introducing Mutton Busters Baby Boots by Justin Boots Justin Boots, a name that captures the essence of Western craftsmanship, has launched an exciting new collection for the tiny trendsetters: Mutton Busters. These infant boots are tailored specifically for babies, ensuring comfort, support, and a stylish touch as they take their first steps into the world. Features...

Continue Reading
Waterdrop Inc. Reports Significant Q3 Growth and Innovation

Updated Category News Views 203

Waterdrop Inc. Reports Impressive Financial Results for Q3 Waterdrop Inc. (NYSE: WDH), a prominent technology platform specializing in insurance and healthcare services, recently announced notable financial outcomes for the quarter that ended on September 30, 2025. This report highlights a commendable net operating revenue of RMB 974.9 million, marking a significant...

Continue Reading
Next Technology Holding Inc. Reports Remarkable H1 2025 Growth

Updated Category News Views 150

Next Technology Holding Inc. Delivers Impressive Financial Results for H1 2025 Next Technology Holding Inc. (NASDAQ: NXTT), a leading technology company focused on AI and Bitcoin investments, has released its financial results, showcasing a remarkable surge in performance for the first half of the year. The company, known for its commitment to creating innovative AI...

Continue Reading